CDK2 and glioblastoma: To test the clinical relevance of CDK2 targeting for GBMs, we then referred to the public database (GDSC32,33, https://www.cancerrxgene.org) and confirmed that GBM cell lines were more sensitive to AZD5438 (CDK2 inhibitor) treatment comparing to LGG cell lines, with lower IC50 (half maximal inhibitory concentration) value (median IC50: 12.20 μM in GBMs vs 72.51 μM in LGGs) (Supplementary Fig. 5E).